For GSK CEO Emma Walmsley, there was good news and bad news in the company’s annual report. | For GSK CEO Emma Walmsley, there was good news and bad news in the company’s annual report. While it ...

Tang Capital Partners already owns 5.3% of Acelyrin’s common stock, the investment company explained in its offer letter (PDF) to Acelyrin ... be a competitor to Amgen's thyroid eye disease ...

Acral Lentiginous Melanoma Market was valued at USD 85 Million in 2023, and is expected to reach USD 122.3 Million in 2033, at a CAGR of 3.80% Lawrence John Prudour +91 91308 55334 ...

Amgen’s revenue bump was down from at least ... One was GSK, with a 1% increase as sales of Arexvy plummeted (PDF) by 70% year over year, largely because the Centers for Disease Control and ...

Investors with a lot of money to spend have taken a bearish stance on Amgen AMGN. And retail traders should know. We noticed this today when the trades showed up on publicly available options ...

Ratings for Amgen AMGN were provided by 9 analysts in the past three months, showcasing a mix of bullish and bearish perspectives. The following table provides a quick overview of their recent ...

THOUSAND OAKS, Calif., Feb. 14, 2025 /PRNewswire/ -- Amgen (NASDAQ: AMGN) will present at Citi's 2025 Virtual Oncology Leadership Summit at 3:00 p.m. ET on Wednesday, Feb. 19, 2025. Jean-Charles ...

In early February, Amgen released financial results for the 4th quarter of 2024, which I was eagerly awaiting. In addition to demonstrating efficacy in the treatment of nasal polyps in Phase 3 ...

Amgen discovers, develops, manufactures and delivers innovative medicines to help millions of patients in their fight against some of the world's toughest diseases. More than 40 years ago, Amgen ...

We recently published a list of the 10 Best Drug Stocks to Buy Now. In this article, we are going to take a look at where Amgen Inc. (NASDAQ:AMGN) stands against other best drug stocks to buy now.